Author

Xin Cheng

Harvard UniversityORCID 0009-0009-9549-5918Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Bose S. KochupurakkaliD· 1 shared Changli Qian· 1 shared Elena V. IvanovaiD· 1 shared Erica M. HoldridgeiD· 1 shared Geoffrey Ira ShapiroiD· 1 shared Gordon James FreemaniD· 1 shared Guruprasad AnandaiD· 1 shared Hao GuiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bose S. KochupurakkalORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyNature CommunicationsPeer-reviewedMay 4, 2026

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer

Xin Cheng, Y Zhang, Changli Qian…·Jean J. Zhao

This study identifies FGFR signaling as a driver of resistance and immune evasion in PIK3CA-driven serous-like endometrial cancer and shows that dual FGFR/PI3K inhibition improves tumor control.

DOI 10.1038/s41467-026-72544-z

mousebulk RNA-seq

𝕏 PostBluesky